| Barchart Demo Center |
$33.10
+0.53 (+1.63%)
as of Oct 1, 2019
as of Oct 1, 2019
| Last | 33.10 |
|---|---|
| Change | +0.53 (+1.63%) |
| Open | 33.05 |
| Prev. Close | 32.57 |
| Today's Range |
32.77
33.53
|
| 52wk Range |
14.34
39.10
|
| Volume | 5,350 |
| Avg Volume | 10,947 |
Perfomance Comparison
| Name | Today | 3-Month | 1-Year |
|---|---|---|---|
| ZYME.TO |
 +1.63% |
 +4.28% |
+67.94% |
| $TXCX |
 -0.05% |
+0.05% |
+7.17% |
| $TXSC |
+0.02% |
+0.30% |
+8.37% |
| DJIA |
+1.21% |
+0.88% |
+7.04% |
| S&P 500 |
+1.09% |
+0.57% |
+8.87% |
Key Statistics
| Annual EPS | -1.55 |
|---|---|
| Dividend Yield | N/A |
| P/E Ratio | N/A |
| Market Capitalization, $K | 1,299,504 |
| Weighted Alpha | +91.80 |
| Standard Deviation | +0.52 |
| Profit Margin | -1.03% |
| Beta | N/A |
Growth Rates
| YTD | +66.16% | |||
| 1-Year | +82.87% |
Opinion
| Sell | Hold | Buy |
Recent Headlines
Zymeworks Announces Election of Directors and Voting
BusinessWire via COMTEX - Fri May 03, 06:45AM EDT
Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical
company developing multifunctional biotherapeutics, is pleased to
announce the detailed voting results on the items of business considered
at(full story)
Zymeworks Reports 2019 First Quarter Financial Results
BusinessWire via COMTEX - Thu May 02, 05:00PM EDT
Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical
company developing multifunctional therapeutics, today reported
financial results for the first quarter ended March 31, 2019.(full story)
Zymeworks Adds Experienced Executives to Management
BusinessWire via COMTEX - Tue Apr 30, 06:45AM EDT
Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical
company developing multifunctional biotherapeutics, today announced it
has expanded its leadership team with the hiring of three new vice
pre(full story)
Daiichi Sankyo Selects Lead Candidate Built on
BusinessWire via COMTEX - Thu Apr 25, 06:45AM EDT
--Zymeworks to receive US$3.5 million commercial license payment from Daiichi Sankyo(full story)
Zymeworks Opens Phase 2 Clinical Trial for ZW25 in
BusinessWire via COMTEX - Mon Apr 15, 06:45AM EDT
Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical
company developing multifunctional therapeutics, today announced it has
initiated its global multicenter Phase 2 clinical trial evaluating ZW25
(full story)